Tesofensine Conjugate
Triple monoamine reuptake inhibitor conjugate researched for indirect metabolic optimization.
Open Tesofensine Conjugate in the 3D analyzerAnalytical specification
| Empirical formula | C22H32Cl2N2O |
|---|---|
| Molecular weight | 411.4 g/mol |
| Isoelectric point (pI) | 8.20 |
| Assay purity (HPLC) | 99.05% |
| Retention time | 4.50 min |
| Peak area / height | 8900 / 750 |
| Reference batch | TE-2026-H04 |
| Research category | Metabolic & Weight Management |
| Amino-acid sequence | Monamine reuptake inhibitor peptide-linked conjugate platform |
Research characteristics
Appetite Signal
Inhibits presynaptic dopamine uptake
Cholinergic Loop
Increases downstream metabolic burn
Brain Target
Stimulates deep hypothalamic nuclei
Vibrational Mode
Highly active structural rotation
Reconstitution
Use the interactive reconstitution calculator to convert vial size (mg), bacteriostatic water volume (ml) and target dose (mcg) into a syringe draw on a standard 100-unit insulin syringe. Open the dosage calculator.
Related metabolic & weight management compounds
Retatrutide (Reta)
Next-generation triple receptor agonist (GLP-1, GIP, GCGR) driving advanced metabolic homeostasis.
Tirzepatide (Tirze)
Dual GIP and GLP-1 receptor agonist targeting glucose homeostasis and body composition dynamics.
Semaglutide
Established GLP-1 receptor agonist mimicking natural incretin hormones with modified clearance curves.
Liraglutide
Acylated human glucagon-like peptide-1 analog designed for clinical metabolic investigation models.
Cagrilintide
Long-acting amylin analogue targeting dual pathways in conjunction with incretin receptor systems.
Mazdutide
Novel dual GLP-1R/GCGR agonist targeting lipid elimination and cellular thermodynamic burn.